Masson, R. Et Al. 2022. Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. The Lancet Neurology , vol.21, no.12 , 1110-1119.

Masson, R., Mazurkiewicz-Bełdzińska, M., Rose, K., Servais, L., Xiong, H., Zanoteli, E., ... Baranello, G.(2022). Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial. The Lancet Neurology , vol.21, no.12, 1110-1119.

Masson, Riccardo Et Al. "Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial," The Lancet Neurology , vol.21, no.12, 1110-1119, 2022

Masson, Riccardo Et Al. "Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial." The Lancet Neurology , vol.21, no.12, pp.1110-1119, 2022

Masson, R. Et Al. (2022) . "Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial." The Lancet Neurology , vol.21, no.12, pp.1110-1119.

@article{article, author={Riccardo Masson Et Al. }, title={Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial}, journal={The Lancet Neurology}, year=2022, pages={1110-1119} }